and to third results Eric, everyone, you, our XXXX conference financial Thank welcome, quarter call.
significant improving During ophthalmic in outcomes the we medications technology. transforming third around Optejet leader quarter, our towards into made from Eyenovia topical a built progress
provides potential readout First and pediatric most progressive a near-term, addressable MicroPine, to opportunity. market entry data approved, multibillion-dollar for are we Phase efficacy myopia our approaching rapidly a if which, III product,
next-generation we profile. making will are profitability for and advances Second, our this progress our are with excited about mean Optejet technology what and the
an mydriasis on FDA-approved we Fourth, Optejet based our Third, ophthalmic profile. cornerstone advancing in serving a clobetasol, Optejet in our the commercializing highly our compounds MydCombi, through partners. clobetasol we have funded advanced desirable late-stage as the product, been technology, development for first product, and launched are partially pipeline development also with second with steroid dry eye product strategic we and our FDA-approved X
myopia our XX Pediatric losing are In globally. States million recognized MicroPine, candidate U.S. atropine into myopia, this due Optejet-based myopia. Now considered for of the dive take vision let's low-dose to of the alone, pediatric United X children and at is epidemic deeper an progressive progressive disease. the both a nearly functional approximately with product in as increasingly million risk
as benefits such children children, ATOM may has what Atropine have due cause Optejet for formulation eye offer lenses lens or do prior contact atropine are their the injury the contact we been not a with proprietary of may youngest to poor always tolerate techniques. studies children eye myopia the insertion progression.
Many lenses who they progression, to administered appropriate beyond and themselves glasses shown drop. at LAMP not putting care be with While myopia and the most our believe could slow for ] and something also of illness traditional well, with are myopia, progressive risk difficulty standard or diagnosed in obtained [ are current younger on
understand Optejet the have come the clinic stores been with consistent patient or With the that in self-administer quickly. the They These with dosing itself the study Phase notably infrequent mirror a when minimal the our III and medication, aiming myriad what X with and information children built-in a or helps of face as device can head Optejet our reduce the the has device of event CHAPERONE we the like Optejet bottle, technology, manipulation staff dosing to track children been Optejet conventional dose years effects tilting with struggles have with have how reviewed drug parental any dosing themselves with familiar supervision. advanced with expect information. eye dosing time because pressed also visit. during the records accessed require as system. anxiety button of dosing been the study device the old with the are atropine an embedded has used.
Each doesn't eye to gentle children firmware in can of young nightly dosed by process drop making our results administer drops. be are engineers This potential medication administration to and of The CHAPERONE and the and parents Throughout doctors and and performance the when the comfortable trial, feels mild achievable.
The dosing side become and is to better dosing mist study. have This minimizes the keeping
well equipped and treating the patients OptiCare we and when with can our parents as their communicate which commercial dose spray administer for as notify important anticipate doctor. caregivers information system, will product, For compliance MicroPine adherence be their the their and to
submission. anticipated plans NDA validate Our working future part engineers are to today as of system on the our
efficacy that Phase year efficacy very committee advance X independent the data we analysis endpoint, study and safety soon accelerated December to forward of indicates the on as to continuing III looking an analysis our FDA pathway the have are updates program soon. early conducted with our If are submission look of upcoming XX. discuss would likely providing towards perform additional an an by achieved and during outcome XXXX. data the virtual and forward on this this analysis a as an We complete NDA CHAPERONE event We review KOL to we
has testing. let's in of process completed subsequent and cartridges manufacturing FDA step Now review preparing our the key now team made X for Gen and first is batches sterilization a this recently Optejet. technology. advances those phase the the are for about with We talk our This drug stability registration
a this foundation are our that path We all leading and would to for expeditious with is developed MydCombi are use believe products the subsequent we for most Optejet. with as registration, provide
including X compatibility greater over to a point lower introduction to XX% costs, Gen As us many first-generation to use a is compliance margins fewer parts more for reminder, the predecessor, our device one as upcoming efficiency the line. with translates the button of planned the This helping inflection It on and advancements product achieve to view its manufacture. our company. Optejet We significant monitoring developed of up efficient and has digital program, OptiCare. with Gen X was also
has into a serve activities, of company, the MydCombi, as a Optejet of no the studies any the device view. regulatory identify as various Now ophthalmology the Obtaining are We more derisked very closely to recognized a approval and a to with Optejet-based a of by worked technology also technology precedent in our with other our containing let's the itself was now FDA there approval point we very for as our device get approval processes MydCombi deeply necessary MydCombi important for Prior to is and allowing products care. that look MydCombi. other of from milestone it combine within to were to product. electronics. Eyenovia eye leader this validation terrific FDA approved, drug
those which understand their learn change felt also truly eye placed more from paradigm perceptions the market doctors Optejet the and and in that using both this into their With MydCombi introducing about week, using to work this We to closely a with XX eye the with of comfortable offices drops. doctors We technicians mind, that XXX in us technicians requires about we and translates MydCombi platform. technology found drops. times, of after about the
X was to was their long experience it professionals that highly We care not improvement X felt when of out especially drops, work dilation eye did did quickly that which those as older was as a who with more substantial also over eye people, children MydCombi dilating found as return to with that last MydCombi eye drops, desirable. pupil and needed
of the now the offices positive months, are As findings, over few a XXX which our acceptance formulary on focused on things: retention these is of converting X offices and key now. right result working force institutions, of sales existing they next another
appointed Executive I'd Medical Chairman. funded over and advance serve significant Consultant. member, well Charles guidance the development Ianchulev, markets, to remain served and Bren, continue reasons. Charlie our to to and our our our keep cover Board experience initiatives. us expertise call served the company He as Founder In has stepped XXXX, Board Board has work a September, Directors. the also from for to personal will and his like we new down since capital recent on has in Chairman as Mather, turning Sean Before been who has to role sufficiently the on of Board change our to our
Sean we are Kern. our this Officer, at both Chief this on to our for over turn We important and that call as to have time the continue Charlie Eyenovia.
At Board resources Bren? point, I'll will pleased vital Operating Bren
